首页|BTK/JAK3双靶点抑制剂的设计合成和生物活性评价

BTK/JAK3双靶点抑制剂的设计合成和生物活性评价

扫码查看
以课题组前期发现的XL-12为先导化合物,通过末端苯环的结构修饰,进一步提高化合物的抗炎活性.设计并合成了 12个目标化合物.所有目标化合物的结构经1H NMR、13C NMR和HRMS确证.体外活性测试结果显示大部分化合物对布鲁顿型酪氨酸激酶(Bruton's tyrosine,BTK)和Janus激酶 3(JAK3)具有较好的酶抑制活性,化合物I-3对Daudi细胞和BaF3-JAK3细胞显示中等的细胞增殖抑制活性.在体外抗炎活性评价中,化合物I-3能有效抑制炎症因子IL-6的产生.此外,在小鼠二甲苯致耳廓肿胀模型中,化合物I-3显示出优于阳性药依鲁替尼(ibrutinib)的抗炎活性.
Design,synthesis and biological study of BTK/JAK3 dual-target inhibitors
In the present study,the compound XL-12 from our previous work was utilized as a lead compound.Through the optimization of the terminal phenyl ring,12 target compounds were designed and synthesized.The structures of all target compounds were confirmed by 1H NMR,13C NMR,and H RMS.In vitro enzyme activity assay showed that most compounds demonstrated significant inhibitory activity toward Bruton's tyrosine kinase(BTK)and Janus kinase 3(JAK3).Among them,compound I-3 exhibited moderate cell proliferation inhibitory activity toward Daudi cells and BaF3-JAK3 cells.In the evaluation of anti-inflammatory activity in vitro,compound I-3 could effectively inhibit the production of inflammatory factors IL-6;besides,it exhibited superior anti-inflammatory activity compared to ibrutinib in xylene-induced ear swelling model in mice.

rheumatoid arthritisBTK inhibitorJAK3 inhibitordual-target inhibitorsanti-inflammatory

岑丽芳、程铭、任玮杰、叶柳、王禄华、郭维博、张强、徐云根

展开 >

中国药科大学药物化学系, 南京 210009

西安新通药物研究股份有限公司, 西安 710077

类风湿性关节炎 BTK抑制剂 JAK3抑制剂 双靶点抑制剂 抗炎

2024

中国药科大学学报
中国药科大学

中国药科大学学报

CSTPCD北大核心
影响因子:0.655
ISSN:1000-5048
年,卷(期):2024.55(1)
  • 16